NASDAQ:UTHR United Therapeutics (UTHR) Stock Price, News & Analysis $350.19 -2.39 (-0.68%) (As of 04:00 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About United Therapeutics Stock (NASDAQ:UTHR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$349.19▼$355.5350-Day Range$320.99▼$372.8152-Week Range$208.62▼$377.03Volume255,226 shsAverage Volume467,710 shsMarket Capitalization$15.53 billionP/E Ratio16.09Dividend YieldN/APrice Target$361.33Consensus RatingModerate Buy Company OverviewUnited Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.Read More… Here’s how to start a “Weekend Side Hustle” from your sofa (Ad)Here’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand. And that’s how you can kickstart your very own “Weekend Side Hustle!” Now that you know that…Let me show you how I target extra income as early as THIS weekend! United Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks93rd Percentile Overall ScoreUTHR MarketRank™: United Therapeutics scored higher than 93% of companies evaluated by MarketBeat, and ranked 87th out of 1,001 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingUnited Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 10 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageUnited Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about United Therapeutics' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth11.53% Earnings GrowthEarnings for United Therapeutics are expected to grow by 11.53% in the coming year, from $24.72 to $27.57 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 16.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.98.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 16.14, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 134.46.Price to Earnings Growth RatioUnited Therapeutics has a PEG Ratio of 1.35. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about United Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.12% of the float of United Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in United Therapeutics has recently decreased by 45.10%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-2.00 Percentage of Shares Shorted5.12% of the float of United Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in United Therapeutics has recently decreased by 45.10%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News Sentiment0.96 News SentimentUnited Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for United Therapeutics this week, compared to 9 articles on an average week.Search InterestOnly 6 people have searched for UTHR on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows7 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $37,673,322.00 in company stock.Percentage Held by Insiders12.50% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about United Therapeutics' insider trading history. UTHR Stock News HeadlinesUnited Therapeutics Co. (NASDAQ:UTHR) CFO Sells $2,855,916.18 in StockOctober 23 at 4:55 AM | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CFO Sells $2,773,016.96 in StockOctober 16, 2024 | insidertrades.comNext opportunity for crypto millionsAccording to Steven Lubka, head of a private equity firm with over $250M in assets under management, "Bitcoin is poised to reach six-figures, no matter who wins the U.S. presidential election…" And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before. Coins that you may not have even heard of before could shoot up 10x, 20x, maybe even 150x in the coming months… October 24, 2024 | Crypto 101 Media (Ad)James Edgemond Sells 7,794 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockOctober 9, 2024 | insidertrades.comJames Edgemond Sells 7,792 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockOctober 2, 2024 | insidertrades.comUnited Therapeutics (NASDAQ:UTHR) versus Akero Therapeutics (NASDAQ:AKRO) Critical ContrastOctober 24 at 5:45 AM | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Stock Price Down 6.8% After Insider SellingOctober 24 at 2:56 AM | americanbankingnews.comTD Cowen Raises United Therapeutics (NASDAQ:UTHR) Price Target to $400.00October 24 at 1:35 AM | americanbankingnews.comSee More Headlines UTHR Stock Analysis - Frequently Asked Questions How have UTHR shares performed this year? United Therapeutics' stock was trading at $219.89 at the start of the year. Since then, UTHR shares have increased by 59.7% and is now trading at $351.25. View the best growth stocks for 2024 here. How were United Therapeutics' earnings last quarter? United Therapeutics Co. (NASDAQ:UTHR) announced its earnings results on Wednesday, July, 31st. The biotechnology company reported $5.85 EPS for the quarter, missing analysts' consensus estimates of $6.33 by $0.48. The business's revenue for the quarter was up 19.8% on a year-over-year basis. Who are United Therapeutics' major shareholders? United Therapeutics' top institutional investors include Swedbank AB (0.93%), Allspring Global Investments Holdings LLC (0.41%), DekaBank Deutsche Girozentrale (0.21%) and Wedge Capital Management L L P NC (0.20%). Insiders that own company stock include Paul A Mahon, Louis W Sullivan, Judy D Olian, James Edgemond, Nilda Mesa, Christopher Causey, Michael Benkowitz, Raymond Dwek, Martine A Rothblatt and Christopher Patusky. View institutional ownership trends. How do I buy shares of United Therapeutics? Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that United Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings7/31/2024Today10/24/2024Next Earnings (Confirmed)10/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:UTHR CUSIP91307C10 CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees1,168Year Founded1996Price Target and Rating Average Stock Price Target$361.33 High Stock Price Target$575.00 Low Stock Price Target$240.00 Potential Upside/Downside+2.6%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)$21.15 Trailing P/E Ratio16.19 Forward P/E Ratio14.25 P/E Growth1.35Net Income$984.80 million Net Margins40.87% Pretax Margin53.54% Return on Equity18.82% Return on Assets15.61% Debt Debt-to-Equity Ratio0.02 Current Ratio4.35 Quick Ratio4.18 Sales & Book Value Annual Sales$2.62 billion Price / Sales5.97 Cash Flow$21.01 per share Price / Cash Flow16.76 Book Value$127.35 per share Price / Book2.77Miscellaneous Outstanding Shares44,356,000Free Float39,197,000Market Cap$15.62 billion OptionableOptionable Beta0.57 Social Links This page (NASDAQ:UTHR) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredNext opportunity for crypto millionsAccording to Steven Lubka, head of a private equity firm with over $250M in assets under management, "Bitcoin ...Crypto 101 Media | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredAmerica’s Election NightmareThanks to a new law signed by President Biden, a small group of powerful people could decide who is installed ...Banyan Hill Publishing | SponsoredIt’s delivered 859% in 2.5 months…We’ve gotten a lot of messages asking… what should we buy if Trump wins? What should we buy if Kamala wins?...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.